NASDAQ:PSTI - Pluristem Therapeutics Stock Price, News & Analysis

-0.06 (-1.38 %)
(As of 09/18/2019 01:01 AM ET)
Today's Range
Now: $4.28
50-Day Range
MA: $4.20
52-Week Range
Now: $4.28
Volume80,672 shs
Average Volume56,756 shs
Market Capitalization$66.55 million
P/E RatioN/A
Dividend YieldN/A
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:PSTI



Sales & Book Value

Annual Sales$50,000.00
Book Value$1.43 per share


Net Income$-35,310,000.00


Market Cap$66.55 million
Next Earnings Date9/26/2019 (Estimated)

Receive PSTI News and Ratings via Email

Sign-up to receive the latest news and ratings for PSTI and its competitors with MarketBeat's FREE daily newsletter.

Pluristem Therapeutics (NASDAQ:PSTI) Frequently Asked Questions

What is Pluristem Therapeutics' stock symbol?

Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."

When did Pluristem Therapeutics' stock split? How did Pluristem Therapeutics' stock split work?

Shares of Pluristem Therapeutics reverse split before market open on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2019. An investor that had 100 shares of Pluristem Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Pluristem Therapeutics' earnings last quarter?

Pluristem Therapeutics Inc. (NASDAQ:PSTI) posted its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.10. View Pluristem Therapeutics' Earnings History.

When is Pluristem Therapeutics' next earnings date?

Pluristem Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, September 26th 2019. View Earnings Estimates for Pluristem Therapeutics.

What price target have analysts set for PSTI?

3 equities research analysts have issued 1-year price targets for Pluristem Therapeutics' stock. Their predictions range from $30.00 to $40.00. On average, they anticipate Pluristem Therapeutics' share price to reach $35.00 in the next twelve months. This suggests a possible upside of 717.8% from the stock's current price. View Analyst Price Targets for Pluristem Therapeutics.

What is the consensus analysts' recommendation for Pluristem Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pluristem Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pluristem Therapeutics.

What are Wall Street analysts saying about Pluristem Therapeutics stock?

Here are some recent quotes from research analysts about Pluristem Therapeutics stock:
  • 1. According to Zacks Investment Research, "PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. " (7/10/2019)
  • 2. Maxim Group analysts commented, "Pluristem provided a shareholder update to highlight upcoming milestones. The company also completed an equity financing on 4/8 raising $21M. We estimate the company has ~$27M in cash on the balance sheet." (4/24/2019)

Has Pluristem Therapeutics been receiving favorable news coverage?

News articles about PSTI stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pluristem Therapeutics earned a news impact score of -2.9 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Pluristem Therapeutics.

Are investors shorting Pluristem Therapeutics?

Pluristem Therapeutics saw a increase in short interest in August. As of August 31st, there was short interest totalling 169,400 shares, an increase of 14.6% from the July 31st total of 147,800 shares. Based on an average trading volume of 68,200 shares, the days-to-cover ratio is presently 2.5 days. Approximately 1.2% of the shares of the stock are sold short. View Pluristem Therapeutics' Current Options Chain.

Who are some of Pluristem Therapeutics' key competitors?

What other stocks do shareholders of Pluristem Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pluristem Therapeutics investors own include Teva Pharmaceutical Industries (TEVA), Protalix Biotherapeutics (PLX), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), BIOLINERX LTD/S (BLRX), Fate Therapeutics (FATE), ImmunoGen (IMGN), AT&T (T), Gilead Sciences (GILD) and Novavax (NVAX).

Who are Pluristem Therapeutics' key executives?

Pluristem Therapeutics' management team includes the folowing people:
  • Mr. Zami Aberman, Chairman & Co-CEO (Age 65)
  • Mr. Yaky Yanay, Pres, Co-CEO & Director (Age 48)
  • Ms. Chen Franco-Yehuda, CFO, Treasurer & Sec. (Age 35)
  • Mr. Boaz Leshem, VP Operations & Manufacturing (Age 59)
  • Ms. Efrat Kaduri, Director of Bus., Investor and PR

Who are Pluristem Therapeutics' major shareholders?

Pluristem Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (33.68%), Sumitomo Mitsui Trust Holdings Inc. (12.30%), Nikko Asset Management Americas Inc. (12.95%), Renaissance Technologies LLC (9.56%), Verition Fund Management LLC (2.43%) and Jane Street Group LLC (1.00%). Company insiders that own Pluristem Therapeutics stock include Mark Germain, Moria Kwiat and Yaky Yanay. View Institutional Ownership Trends for Pluristem Therapeutics.

Which major investors are selling Pluristem Therapeutics stock?

PSTI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Van ECK Associates Corp. View Insider Buying and Selling for Pluristem Therapeutics.

Which major investors are buying Pluristem Therapeutics stock?

PSTI stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Verition Fund Management LLC, Jane Street Group LLC and United Capital Financial Advisers LLC. Company insiders that have bought Pluristem Therapeutics stock in the last two years include Moria Kwiat and Yaky Yanay. View Insider Buying and Selling for Pluristem Therapeutics.

How do I buy shares of Pluristem Therapeutics?

Shares of PSTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pluristem Therapeutics' stock price today?

One share of PSTI stock can currently be purchased for approximately $4.28.

How big of a company is Pluristem Therapeutics?

Pluristem Therapeutics has a market capitalization of $66.55 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-35,310,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. Pluristem Therapeutics employs 172 workers across the globe.View Additional Information About Pluristem Therapeutics.

What is Pluristem Therapeutics' official website?

The official website for Pluristem Therapeutics is

How can I contact Pluristem Therapeutics?

Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 31905. The biotechnology company can be reached via phone at 972-74-710-7259 or via email at [email protected]

MarketBeat Community Rating for Pluristem Therapeutics (NASDAQ PSTI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  309 (Vote Outperform)
Underperform Votes:  229 (Vote Underperform)
Total Votes:  538
MarketBeat's community ratings are surveys of what our community members think about Pluristem Therapeutics and other stocks. Vote "Outperform" if you believe PSTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/18/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel